← ANALYST RATINGS · TIPRANKS
Rocket Pharmaceuticals (RCKT): analyst forecast and price target
Analyst consensus
Moderate Buy7 Buy4 Hold0 Sell
Ratings of 11 analysts in the last 3 months12-month forecast
Based on 11 price targets given in the last 3 months, the average target is $9.50, the highest $15.00, the lowest $4.00. The average is +335.8% from the last price of $2.18.
Analyst ratings 22
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.50 → $2.00−20.0% | Hold | −8.3% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.50 → $2.00−20.0% | Hold | −8.3% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 → $2.00−20.0% | Hold | −8.3% | Reiterated | 14.10.26on TipRanks 06:05 | — | |
| Gil Blum★★★★★★★★★★#949 · hits 43% · avg +12.5% | Needham | $9.00 | Buy | +312.8% | Reiterated | 07.10.26on TipRanks Oct 8 04:50 | +2.5%next day +4.2% · 5 days −11.8% | ↗ |
| Richard Law CFA★★★★★★★★★★#3237 · hits 50% · avg +9.1% | Goldman Sachs | $3.00 → $4.00+33.3% | Hold | +83.5% | Upgrade | 07.10.26on TipRanks Oct 8 03:15 | +2.5%next day +4.2% · 5 days −11.8% | ↗ |
| Mani Foroohar★★★★★★★★★★#11266 · hits 43% · avg −2.1% | Leerink Partners | $7.00 → $4.00−42.9% | Hold | +83.5% | Reiterated | 07.10.26on TipRanks 09:10 | +2.5%next day +4.2% · 5 days −11.8% | ↗ |
| Yun Zhong★★★★★★★★★★#12228 · hits 38% · avg −9.6% | Wedbush | $15.00 | Buy | +588.1% | Reiterated | 07.10.26on TipRanks 07:25 | +2.5%next day +4.2% · 5 days −11.8% | ↗ |
| Whitney Ijem★★★★★★★★★★#537 · hits 48% · avg +20.2% | Canaccord Genuity | $10.00 | Buy | +358.7% | Reiterated | 07.10.26on TipRanks 07:11 | +2.5%next day +4.2% · 5 days −11.8% | ↗ |
| Michael Ulz★★★★★★★★★★#6183 · hits 43% · avg +0.9% | Morgan Stanley | $5.00 | Hold | +129.4% | Reiterated | 07.10.26on TipRanks 06:15 | +2.5%next day +4.2% · 5 days −11.8% | ↗ |
| Jason Zemansky★★★★★★★★★★#467 · hits 60% · avg +21.6% | Bank of America Securities | $10.00 | Buy | +358.7% | Reiterated | 07.10.26on TipRanks 05:45 | +2.5%next day +4.2% · 5 days −11.8% | ↗ |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.50 | Hold | +14.7% | Upgrade | 07.10.26on TipRanks 01:05 | — | |
| Joshua Schimmer★★★★★★★★★★#407 · hits 51% · avg +19.0% | Cantor Fitzgerald | $15.00 | Buy | +588.1% | Reiterated | 06.10.26on TipRanks Oct 7 07:45 | −5.5%next day +2.5% · 5 days −7.1% | ↗ |
| Patrick Dolezal★★★★★★★★★★#1287 · hits 44% · avg +15.1% | LifeSci Capital | $12.00 | Buy | +450.5% | Reiterated | 02.10.26on TipRanks 13:35 | −1.9%next day +1.3% · 5 days −1.2% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.50 | Hold | +14.7% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.50 | Sell | +14.7% | Downgrade | 01.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.50 | Hold | +14.7% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.50 | Hold | +14.7% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.50 | Hold | +14.7% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 | Hold | +14.7% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| Mani Foroohar★★★★★★★★★★#11266 · hits 43% · avg −2.1% | Leerink Partners | — | Hold | — | Reiterated | 16.09.26on TipRanks 08:50 | +2.5%next day −0.6% · 5 days −15.3% | ↗ |
| Gil Blum★★★★★★★★★★#949 · hits 43% · avg +12.5% | Needham | $9.00 | Buy | +312.8% | Upgrade | 16.09.26on TipRanks 06:25 | +2.5%next day −0.6% · 5 days −15.3% | ↗ |
| Jason Zemansky★★★★★★★★★★#467 · hits 60% · avg +21.6% | Bank of America Securities | $10.00 | Buy | +358.7% | Reiterated | 15.09.26on TipRanks Sep 16 04:55 | −0.1%next day +2.5% · 5 days −4.1% | ↗ |
| Patrick Dolezal★★★★★★★★★★#1287 · hits 44% · avg +15.1% | LifeSci Capital | $12.00 | Buy | +450.5% | Reiterated | 15.09.26on TipRanks 12:25 | −0.1%next day +2.5% · 5 days −4.1% | ↗ |
| Yun Zhong★★★★★★★★★★#12228 · hits 38% · avg −9.6% | Wedbush | $15.00 | Buy | +588.1% | Reiterated | 15.09.26on TipRanks 11:15 | −0.1%next day +2.5% · 5 days −4.1% | ↗ |
| Keay Nakae★★★★★★★★★★#3914 · hits 40% · avg +3.0% | Chardan Capital | $11.00 | Buy | +404.6% | Reiterated | 15.09.26on TipRanks 09:50 | −0.1%next day +2.5% · 5 days −4.1% | ↗ |
| Whitney Ijem★★★★★★★★★★#537 · hits 48% · avg +20.2% | Canaccord Genuity | $10.00 | Buy | +358.7% | Reiterated | 12.08.26on TipRanks 07:20 | −2.8%next day −2.7% · 5 days +7.5% | ↗ |
| Michael Ulz★★★★★★★★★★#6183 · hits 43% · avg +0.9% | Morgan Stanley | $5.00 | Hold | +129.4% | Assigned | 12.08.26on TipRanks Aug 11 09:45 | −3.5%next day −2.8% · 5 days −4.2% | ↗ |
| Joshua Schimmer★★★★★★★★★★#407 · hits 51% · avg +19.0% | Cantor Fitzgerald | $15.00 | Buy | +588.1% | Reiterated | 10.08.26on TipRanks Aug 11 07:55 | +0.9%next day −3.5% · 5 days −6.5% | ↗ |
| Tara Bancroft★★★★★★★★★★#361 · hits 55% · avg +30.3% | TD Cowen | — | Hold | — | Reiterated | 10.08.26on TipRanks Aug 11 02:45 | +0.9%next day −3.5% · 5 days −6.5% | ↗ |
| Tessa Romero★★★★★★★★★★#805 · hits 57% · avg +21.7% | J.P. Morgan | — | Sell | — | Reiterated | 02.04.26on TipRanks Apr 5 14:15 | −2.0%next day −3.0% · 5 days −5.3% | ↗ |
| Richard Law CFA★★★★★★★★★★#3237 · hits 50% · avg +9.1% | Goldman Sachs | $4.69 → $3.00−36.0% | Sell | +37.6% | Reiterated | 27.03.26on TipRanks 07:50 | −17.9%next day −8.3% · 5 days −12.1% | ↗ |
| Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% | Evercore ISI | $5.00 | Hold | +129.4% | Reiterated | 17.12.25on TipRanks Dec 18 06:50 | −3.6%next day −2.0% · 5 days +4.2% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Rocket Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $10.88 at a price of $2.63 (+313.5%); now: $9.50 at $2.18 (+335.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 9 | 6 | 9 | 13 | 19 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 6 | 3 | 2 | 4 | 6 | 9 |
| Sell | 3 | 1 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.40 (from $-0.43 to $-0.30). Last quarter: $1.08.
Best top-analyst consensus in the sector · Healthcare
About Rocket Pharmaceuticals
- CEO: Gaurav D. Shah
- Employees: 202
- 9 Cedarbrook Drive, Cranbury, NJ, 08512, US
- rocketpharma.com
Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs. It is currently progressing three ex vivo lentiviral vector therapies aimed at specific genetic conditions: Fanconi anemia, characterized by a bone marrow defect that hinders blood cell production; leukocyte adhesion deficiency-I, an inherited disorder resulting in a compromised immune system; and pyruvate kinase deficiency, a rare autosomal recessive red blood cell ailment leading to chronic non-spherocytic hemolytic anemia. Complementing these, Rocket Pharmaceuticals also has an in vivo adeno-associated virus program underway for Danon disease, a serious multi-organ lysosomal storage disorder that tragically often results in early mortality due to heart failure. To facilitate its extensive research and development efforts, the company has established key licensing partnerships with esteemed institutions such as the Fred Hutchinson Cancer Research Center, European research bodies including CIEMAT and its collaborators (Centro de Investigacion Biomedica En Red and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz), UCL Business PLC (in conjunction with CIEMAT), The Regents of the University of California, and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. maintains its primary corporate location in Cranbury, New Jersey.
Data from the stock’s TipRanks forecast page, read 14 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗